Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 620 participants.
Also called NCT07835581
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 620 participants
- Sponsor
- Registry
-
NCT07835581 -
2026-528156-15-00
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07835581. Randomized; no masking; primary purpose treatment. Start 2026-10 (anticipated); primary completion 2029-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation
- Acronym
- LEGACY
- Condition
- Kidney Transplant Rejection
- Intervention (Drug)
- Tegoprubart
- Intervention (Drug)
- Tacrolimus
- Lead sponsor
- Eledon Pharmaceuticals
Record details
- Record id
cardio:ct-nct07835581- Content hash
d9f6322b6bcb0226d2e665e22ca0b6e4d16204bb57b3d9d906dadc18af6a0a9a